Because clinical trials are conducted under widely varying conditions, adverse reaction rates
observed in the clinical trials of a drug cannot be directly compared to rates in the clinical
trials of another drug and may not reflect the rates observed in clinical practice.
Nitisinone was studied in one open-label, uncontrolled study of 207 patients with HT-1, ages
0 to 22 years at enrollment (median age 9 months), who were diagnosed with HT-1 by the
presence of succinylacetone in the urine or plasma. The starting dose of nitisinone was 0.3 to
0.5 mg/kg twice daily, and the dose was increased in some patients to 1 mg/kg twice daily
based on weight, biochemical, and enzyme markers. The recommended starting dosage of
nitisinone is 0.5 mg/kg twice daily
[see Dosage and Administration (2.1)]. Median duration
of treatment was 22 months (range 0.1 to 80 months).
The most serious adverse reactions reported during nitisinone treatment were
thrombocytopenia, leukopenia, porphyria, and ocular/visual complaints associated with
elevated tyrosine levels
[see Warnings and Precautions (5.1, 5.2)]. Fourteen patients
experienced ocular/visual events. The duration of the symptoms varied from 5 daysto 2 years.
Six patients had thrombocytopenia, three of which had platelet counts 30,000/microL or
lower. In 4 patients with thrombocytopenia, platelet counts gradually returned to normal
(duration up to 47 days) without change in nitisinone dose. No patients developed infections
or bleeding as a result of the episodes of leukopenia and thrombocytopenia.
Patients with HT- 1 are at increased risk of developing porphyric crises, hepatic neoplasms,
and liver failure requiring liver transplantation. These complications of HT- 1 were observed
in patients treated with nitisinone for a median of 22 months during the clinical trial (liver
transplantation 13%, liver failure 7%, malignant hepatic neoplasms 5%, benign hepatic
neoplasms 3%, porphyria 1%).
The most common adverse reactions reported in the clinical trial are summarized in Table 1.
Table 1: Most Common Adverse Reactions in Patients with HT-1 Treated with Nitisinone*
| Elevated tyrosine levels | >10% |
| Leukopenia | 3% |
| Thrombocytopenia | 3% |
| Conjunctivitis | 2% |
| Corneal opacity | 2% |
| Keratitis | 2% |
| Photophobia | 2% |
| Eye pain | 1% |
| Blepharitis | 1% |
| Cataracts | 1% |
| Granulocytopenia | 1% |
| Epistaxis | 1% |
| Pruritus | 1% |
| Exfoliate dermatitis | 1% |
| Dry skin | 1% |
| Maculopapular rash | 1% |
| Alopecia | 1% |
*reported in at least 1% of patients
Adverse reactions reported in less than 1% of the patients, included death, seizure, brain
tumor, encephalopathy, hyperkinesia, cyanosis, abdominal pain, diarrhea, enanthema,
gastrointestinal hemorrhage, melena, elevated hepatic enzymes, liver enlargement,
hypoglycemia, septicemia, and bronchitis.